Myriad Genetics set to launch CardiaRisk genetic test for high blood pressure in January.
This article was originally published in The Gray Sheet
Executive Summary
MYRIAD GENETICS' CARDIARISK GENETIC HIGH BLOOD PRESSURE TEST LAUNCH is on track for mid-January, according to the company. Used to identify patients with hypertension who have a genetic variant that makes them particularly sensitive to sodium and who are at risk of heart disease, kidney failure and stroke, the test will be marketed to physicians via an outside sales force at a price of $300-400, the firm says.